| Outcome Measures: |
Primary: eGFR slope, eGFR decline after randomization between 2 arms, from randomization to renal replacement therap, study completion or censoring event, upto 96 weeks | Secondary: Renal composite outcome, 1. Cardiovascular or renal death. 2. ESRD: sustained eGFR \<5 mL/min/1.73m2, chronic dialysis or renal transplantation. 3. \>50% sustained decline in eGFR (by the Modification of Diet in Renal Disease equation)., from randomization to study completion or censoring event, upto 96 weeks|Renal and heart failure composite outcome, 1. renal composite outcome 2. Acute kidney injury (increase in serum creatinine ≥1.5 times baseline within 7 days). 3. Hospitalization for heart failure., from randomization to study completion or censoring event, upto 96 weeks|Renal and cardiovascular composite outcome, 1. Renal and heart failure composite outcome. 2. 5P-Major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina or coronary/peripheral artery revascularization)., from randomization to study completion or censoring event, upto 96 weeks
|
